Quinalizarin

CAS No. 81-61-8

Quinalizarin( Quinalizarin | )

Catalog No. M16041 CAS No. 81-61-8

Quinalizarin is a potent, selective and cell-permeable inhibitor of CK2 with Ki of 58 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Quinalizarin
  • Note
    Research use only, not for human use.
  • Brief Description
    Quinalizarin is a potent, selective and cell-permeable inhibitor of CK2 with Ki of 58 nM.
  • Description
    Quinalizarin is a potent, selective and cell-permeable inhibitor of CK2 with Ki of 58 nM; shows selectivity over DYRK1a, PIMs, HIPK2, MNK1, ERK8 and PKD1; inhibits endogenous CK2 and induces apoptosis more efficiently than Emodin in Jurkat cells; reduces cell viability with emphasis on adenocarcinoma cells harboring EGFR sensitive mutation, suppresses migration, and accelerates apoptosis in different human lung cancer cell lines.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Quinalizarin |
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Casein Kinase
  • Recptor
    Casein Kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    81-61-8
  • Formula Weight
    272.212
  • Molecular Formula
    C14H8O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=C2C(O)=CC=C1O)C3=CC=C(O)C(O)=C3C2=O
  • Chemical Name
    1,2,5,8-Tetrahydroxyanthracene-9,10-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cozza G, et al. Biochem J. 2009 Jul 15;421(3):387-95. 2. Zhou Y, et al. Indian J Cancer. 2015 Dec;52 Suppl 2:e119-24. 3. Pan X, et al. Int J Oncol. 2016 Mar;48(3):1073-84.
molnova catalog
related products
  • CX-4945 sodium salt

    A potent, selective, orally bioavailable, ATP-competitive inhibitor of protein kinase CK2 with Ki of 0.38 nM, CK2α IC50 of 1 nM.

  • SGI-7079

    SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors.

  • Longdaysin

    Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 μM). It also can inhibit ERK2 (IC50: 52 μM).